Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE, Gray Heppner D Jr, Moris P, Ofori-Anyinam O, Krzych U, Tornieporth N, McKinney D, Delchambre M, Ockenhouse CF, Voss G, Holland C, Beckey JP, Ballou WR, Cohen J; RTS,S/TRAP Group. Kester KE, et al. Among authors: tornieporth n. Vaccine. 2014 Nov 20;32(49):6683-91. doi: 10.1016/j.vaccine.2014.06.033. Epub 2014 Jun 18. Vaccine. 2014. PMID: 24950358 Free article. Clinical Trial.
Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres.
Dentico P, Crovari P, Lai PL, Ponzio F, Safary A, Pellegrino A, Meurice F, Di Pasquale A, Tornieporth N, Volpe A, Icardi G. Dentico P, et al. Among authors: tornieporth n. Vaccine. 2002 Nov 1;20(31-32):3725-30. doi: 10.1016/s0264-410x(02)00356-0. Vaccine. 2002. PMID: 12399201 Clinical Trial.
Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.
Epstein JE, Charoenvit Y, Kester KE, Wang R, Newcomer R, Fitzpatrick S, Richie TL, Tornieporth N, Heppner DG, Ockenhouse C, Majam V, Holland C, Abot E, Ganeshan H, Berzins M, Jones T, Freydberg CN, Ng J, Norman J, Carucci DJ, Cohen J, Hoffman SL. Epstein JE, et al. Among authors: tornieporth n. Vaccine. 2004 Apr 16;22(13-14):1592-603. doi: 10.1016/j.vaccine.2004.01.031. Vaccine. 2004. PMID: 15068840 Clinical Trial.
Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine.
Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG; MSP-1 Working Group. Ockenhouse CF, et al. Among authors: tornieporth n. Vaccine. 2006 Apr 5;24(15):3009-17. doi: 10.1016/j.vaccine.2005.11.028. Epub 2005 Nov 28. Vaccine. 2006. PMID: 16356603 Clinical Trial.
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ. Bojang KA, et al. Among authors: tornieporth n. Vaccine. 2005 Jul 14;23(32):4148-57. doi: 10.1016/j.vaccine.2005.03.019. Epub 2005 Apr 15. Vaccine. 2005. PMID: 15964483 Clinical Trial.
Epidemiology of travelers' diarrhea: details of a global survey.
Steffen R, Tornieporth N, Clemens SA, Chatterjee S, Cavalcanti AM, Collard F, De Clercq N, DuPont HL, von Sonnenburg F. Steffen R, et al. Among authors: tornieporth n. J Travel Med. 2004 Jul-Aug;11(4):231-7. doi: 10.2310/7060.2004.19007. J Travel Med. 2004. PMID: 15541226 Free article.
Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months.
Usonis V, Meriste S, Bakasenas V, Lutsar I, Collard F, Stoffel M, Tornieporth N. Usonis V, et al. Among authors: tornieporth n. Vaccine. 2005 Apr 8;23(20):2602-6. doi: 10.1016/j.vaccine.2004.11.062. Vaccine. 2005. PMID: 15780442 Clinical Trial.
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.
Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR; RTS,S Malaria Vaccine Evaluation Group. Kester KE, et al. Among authors: tornieporth n. Vaccine. 2007 Jul 20;25(29):5359-66. doi: 10.1016/j.vaccine.2007.05.005. Epub 2007 May 30. Vaccine. 2007. PMID: 17574311 Clinical Trial.
62 results